David Hopkinson Sells 33,556 Shares of Tilray Brands (NASDAQ:TLRY) Stock

Tilray Brands, Inc. (NASDAQ:TLRY) Director David Hopkinson sold 33,556 shares of the stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $6.94, for a total value of $232,878.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Tilray Brands Trading Down 11.8%

NASDAQ:TLRY opened at $6.94 on Friday. The company has a quick ratio of 1.66, a current ratio of 2.79 and a debt-to-equity ratio of 0.19. Tilray Brands, Inc. has a 1-year low of $3.51 and a 1-year high of $23.20. The firm has a market capitalization of $808.86 million, a price-to-earnings ratio of -0.51 and a beta of 2.00. The stock has a fifty day simple moving average of $7.03 and a 200 day simple moving average of $9.51.

Tilray Brands (NASDAQ:TLRY) last released its quarterly earnings results on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.10). Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. The company had revenue of $206.73 million during the quarter, compared to analyst estimates of $201.35 million. During the same quarter last year, the business earned ($0.87) EPS. Sell-side analysts forecast that Tilray Brands, Inc. will post -0.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on TLRY shares. Wall Street Zen upgraded Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. TD Cowen decreased their price objective on Tilray Brands from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, March 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, January 21st. Canaccord Genuity Group started coverage on Tilray Brands in a research report on Tuesday, January 27th. They set a “hold” rating for the company. Finally, Zacks Research upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tilray Brands currently has an average rating of “Hold” and an average target price of $11.50.

Tilray Brands News Summary

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Federal rescheduling and a consequential tax change (the effective end of 280E for qualifying medical operators) materially improves cash flow for U.S. plant-touching MSOs — a sector-wide financial catalyst that lifted cannabis stocks broadly. The Cannabis Sector’s Billion-Dollar Tax Cut
• Positive Sentiment: Tilray issued statements positioning itself for U.S. expansion and highlighted its medical and beverage businesses as growth levers — management messaging supports a longer-term bull case if U.S. opportunities materialize. Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
• Positive Sentiment: Consumer/beverage initiatives (BrewDog USA lineup) highlight diversified revenue streams beyond cannabis, which could help margins and investor perception over time. BrewDog USA Doubles Down on Headliners
• Positive Sentiment: Heavy call-option buying indicates speculative bullish interest that can amplify upside if sentiment reaccelerates. (Options flow reported April 22.)
• Neutral Sentiment: Intraday trading experienced a Limit Up/Limit Down (LULD) pause — a mechanical volatility control that signals high intraday moves but not a new fundamental development.
• Neutral Sentiment: CEO media appearances reiterate the opportunity if U.S. rules loosen, providing color but no immediate revenue impact. Tilray CEO on Possible US Cannabis Reclassification
• Negative Sentiment: “Sell-the-news” reversal and dilution overhang: the initial rally tied to Schedule III headlines faded as traders took profits, and market attention returned to an at-the-market (ATM) equity program (filed earlier in April) that could add supply pressure. Tilray sinks as Schedule III headline turns into a “sell-the-news” reversal
• Negative Sentiment: Insider selling: a director sold ~33,556 shares recently — a signal some investors interpret as caution (though timing and intent can vary). Form 4 — David G. Hopkinson Sale
• Negative Sentiment: Fundamentals still weigh: Tilray’s recent quarter missed EPS estimates and the company remains loss-making with negative margins — investors worry about funding needs and whether newfound policy tailwinds translate quickly into improved earnings for Tilray specifically.

Institutional Investors Weigh In On Tilray Brands

Institutional investors have recently made changes to their positions in the company. Silverlake Wealth Management LLC acquired a new stake in shares of Tilray Brands during the 3rd quarter valued at about $25,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Tilray Brands during the 3rd quarter valued at about $25,000. Unified Investment Management acquired a new stake in shares of Tilray Brands during the 3rd quarter valued at about $26,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Tilray Brands during the 3rd quarter valued at about $30,000. Finally, HighPoint Advisor Group LLC acquired a new stake in shares of Tilray Brands during the 3rd quarter valued at about $33,000. 9.35% of the stock is currently owned by institutional investors and hedge funds.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.